Navigation Links
King Pharmaceuticals Announces Plan to Present Results from Phase,III Clinical Trial Evaluating ALTACE as Monotherapy and in,Combination with Hydrochlorothiazide at the American Society of,Hypertension Annual Meeting

BRISTOL, Tenn.--(BUSINESS WIRE)--May 8, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that the results from a Phase III clinical trial for its ALTACE(R) (ramipril) diuretic combination product will be presented at the American Society of Hypertension's Twenty-Second Annual Scientific Meeting in a poster on Saturday, May 19, 2007 at the Hyatt Regency Hotel, Chicago, Illinois. The poster presentation will be available for review from 10 AM to 6 PM CDT. The Company previously announced that it has positive top-line results from the clinical trial evaluating the efficacy and safety of the Company's ALTACE(R) diuretic combination product in the treatment of hypertension.

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the Company's plan to present the Phase III results for the Company's ALTACE(R) diuretic combination product. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on King's ability to present the Phase III results for its ALTACE(R) diuretic combination
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/21/2014)... /PRNewswire-iReach/ -- ScriptPro has been certified by the ... Security Framework (CSF). According to Russ Hailey ... appreciate this rigorous, top-to-bottom audit. Security-minded customers depend ... signifies. Our business partners need to know we ... PROCESS: ScriptPro,s internal security processes and controls were ...
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... SAN FRANCISCO , Aug. 21, 2014 ... U.S. Food and Drug Administration (FDA) has ... to detect atrial fibrillation (AFib), the most ... analysis process (algorithm) instantly detects if patients ... recordings taken on the mobile phone based ...
Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
... Industry-Funded Immune Globulin Study Uncovers Sample,Manipulation, Design ... -- An analysis,released today critically examined a ... autism and Rh immune globulin,(RhIg) injections, some ... extensive design flaws, the,analysis uncovered manipulation of ...
... OSS, the Netherlands, June 27, 2007-Organon, the human,healthcare ... two,out of three Phase III clinical trials with ... have reached,their randomization target. , ,Corifollitropin alfa ... first of a new class of gonadotropins (a ...
Cached Medicine Technology:Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 2Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 3Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:8/21/2014)... August 21, 2014 Xarelto lawsuit ( ... patients to suffer uncontrollable internal bleeding and other serious ... LLP reports. According to court documents, a wrongful death ... Court, Easter District of New York by the family ... bleeding event that was allegedly caused by Xarelto. Among ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 ... products manufactured by Boston Scientific has begun in ... first bellwether trial. The Rottenstein Law Group LLP, ... women with claims of harm stemming from the ... a claim for compensation for injuries suffered at ...
(Date:8/21/2014)... Revista, a one-stop source for healthcare ... is “on a roll.” Today, the Annapolis-based company ... Southeast, Mid-Atlantic and Midwest areas of the country ... available, comprehensive medical property database tracking these regions. ... including existing and recently added, is 34,549. This ...
(Date:8/21/2014)... 2014 (HealthDay News) -- In a new review of ... avoid eating tuna due to concerns about mercury exposure. ... second only to shrimp as the most commonly eaten ... to avoid all tuna," Jean Halloran, director of food ... Consumer Reports, said in a news release from the ...
(Date:8/21/2014)... August 21, 2014 Sasha is a 10 ... Sasha is getting a little older, and is having trouble ... Sasha just happens to have an owner who purchased a ... had an accident, and could no longer get up and ... her finished basement. She had tried a stair lift, ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2
... circulating blood and important in blood clotting, can promote ... into the brain, triggering inflammation that leads to MS-related ... Diego (UCSD) School of Medicine have identified a fibrin-derived ... models of MS, reducing MS symptoms. ,“Current ...
... A study by Drs Benjamin Kile and David Huang found ... This discovery is sure //to raise the hope of formulating ... platelets stored in blood banks. This will in turn increase ... ,An undesirable side effect of cancer chemotherapy ...
... found if given a choice of exercising alone, with ... age, most adults would rather exercise with others in ... provide useful insight into the preferences of older exercisers, ... initiatives [in communities around the world],” said lead researcher ...
... have come out with study results that encourage health care ... marked by the presence of tumor cells in ... may be a definite clue to chances of reccurence ... with risks of the cancer staging a comeback. ...
... wife Elizabeth Edwards has been diagnosed with// a recurrent case ... right rib bone and hence classified as metastatic or stage ... and underwent treatment, was cancer free for the last two ... conference in North Carolina that she had sought medical treatment ...
... study finds that improving the institutional culture (ethos) of ... on bad habits like// smoking, drinking, drug abuse and ... of Hygiene and Tropical Medicine's Centre for Research on ... teenage pregnancy are major public health challenges and argue ...
Cached Medicine News:Health News:Inhibiting Blood to Save the Brain 2Health News:Improved Platelet Life Span Increases Better Patient Care 2Health News:Exercising With Peers Has Added Appeal 2Health News:Doctors Warned to Keep Track of Tumorous Lymph Nodes 2Health News:Doctors Hopeful for Elizabeth Edwards 2Health News:Improve School Ethos to Combat Teen Evils 2
... King LT™ is a superior, disposable supraglottic ... advances in materials and design to provide ... LT™ emergency airway is a safe, reliable, ... emergency ventilation when direct laryngoscopy is not ...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... Available in even sizes 20-36F. Single use. ... patient comfort. The Latex-Free Robertazzi is the ... offering the best solution for latex sensitivity. ... offer a quality latex-free product as your ...
Bag of 9 airways 20-36 French (1234) or 4 airways 12-18 French (1233). Includes four foil packages of lubricating jelly....
Medicine Products: